AI Summary

CAR‑T cell therapies have changed treatment for many blood cancers, but applying them to solid tumors like liver, breast, or lung cancer has been harder. The difficulty stems partly from the lack of suitable target structures on solid‑tumor cells. Immunotherapies usually aim at tumor‑specific features that also drive growth, but such mutations are not always present or usable in solid cancers.

AI summaries can be wrong sometimes—always verify important details using the source article.